Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.45 |
| ▸ | BACE1 | P56817 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.41 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12862895 | 0.87 | RBP4 (0.33) | GPR119BACE1MAPTMAPK1 | |
| SCHEMBL13996370 | 0.81 | MAPK1 (0.53) | GPR119BACE1ALDH1A1LMNAMAPT | |
| SCHEMBL5363421 | 0.80 | MAPK1 (0.51) | GPR119BACE1ALDH1A1LMNAMAPT | |
| SCHEMBL30659371 | 0.80 | MAPK1 (0.51) | GPR119BACE1ALDH1A1LMNAMAPT | |
| SCHEMBL5357355 | 0.77 | GPR119 (0.46) | GPR119BACE1ALDH1A1LMNAMAPT | |
| SCHEMBL165582 | 0.77 | GPR119 (0.46) | GPR119BACE1ALDH1A1LMNAMAPT | |
| SCHEMBL21995746 | 0.76 | NAMPT (0.50) | GPR119BACE1ALDH1A1LMNAMAPT | |
| SCHEMBL13244108 | 0.76 | CRBN (0.53) | GPR119BACE1ALDH1A1LMNAMAPT | |
| SCHEMBL31565096 | 0.76 | GPR119 (0.47) | GPR119MAPK1 | |
| SCHEMBL13749317 | 0.75 | UCHL1 (0.49) | GPR119ALDH1A1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7964603-B2 | Substituted tetrahydro-quinoline-sulfonamide compounds, their preparation and use as medicaments | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-06-21 | — | — | US | disclosed |
| US-7964603-B2 | Substituted tetrahydro-quinoline-sulfonamide compounds, their preparation and use as medicaments | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-06-21 | — | — | US | disclosed |
| US-7964603-B2 | Substituted tetrahydro-quinoline-sulfonamide compounds, their preparation and use as medicaments | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-06-21 | — | — | US | disclosed |
| EP-2016943-B1 | Substituted tetrahydro-quinoline-sulfonamide compounds, their preparation and use as medicaments | ESTEVE LABOR DR (ES) | 2011-02-23 | — | — | EP | disclosed |
| US-20090030013-A1 | SUBSTITUTED TETRAHYDRO-QUINOLINE-SULFONAMIDE COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIES DEL DR. ESTEVE, S.A. (ES) | 2009-01-29 | — | — | US | disclosed |
| US-20090030013-A1 | SUBSTITUTED TETRAHYDRO-QUINOLINE-SULFONAMIDE COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIES DEL DR. ESTEVE, S.A. (ES) | 2009-01-29 | — | — | US | disclosed |
| US-20090030013-A1 | SUBSTITUTED TETRAHYDRO-QUINOLINE-SULFONAMIDE COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIES DEL DR. ESTEVE, S.A. (ES) | 2009-01-29 | — | — | US | disclosed |
| EP-2016943-A1 | Substituted tetrahydro-quinoline-sulfonamide compounds, their preparation and use as medicaments | Laboratorios del Dr. Esteve S.A. (ES) | 2009-01-21 | — | — | EP | disclosed |
| EP-2016943-A1 | Substituted tetrahydro-quinoline-sulfonamide compounds, their preparation and use as medicaments | Laboratorios del Dr. Esteve S.A. (ES) | 2009-01-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030013-A1 | SUBSTITUTED TETRAHYDRO-QUINOLINE-SULFONAMIDE COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS | HTR6, HTR5A, HTR7 | GPR119 522/4885BACE1 2845/4885ALDH1A1 1846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.